Biological molecules in clinical stroke trials

Stroke remains a leading cause of disability and mortality all over the world despite the efforts made towards improving treatment. Most of the clinical studies have not shown significant beneficial effects in the evaluation of various molecules for their neuroprotection and neuro-recovery promoting...

Full description

Saved in:

Bibliographic Details
Published in:	Romanian journal of neurology Vol. 12; no. 4; pp. 175 - 179
Main Authors:	Stan, Adina Dora, Birle, Codruta, Slavoaca, Dana
Format:	Journal Article
Language:	English
Published:	Amaltea Medical Publishing House 31-12-2013
Subjects:	multimodal neuroprotection neurorecovery pleiotropic drugs
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Stroke remains a leading cause of disability and mortality all over the world despite the efforts made towards improving treatment. Most of the clinical studies have not shown significant beneficial effects in the evaluation of various molecules for their neuroprotection and neuro-recovery promoting properties. The new concept of multimodal, pleiotropic drugs has opened new perspectives in this field. This review focuses on clinical stroke studies with biologically active molecules such as erythropoietin, granulocyte-colony stimulating factor and Cerebrolysin.
ISSN:	1843-8148 2069-6094
DOI:	10.37897/RJN.2013.4.2